Universal Diagnostics SL - Product Pipeline Analysis, 2024 Update

Summary

Universal Diagnostics SL (Universal DX) is a biomedicine company that develops blood-based screening tests for the early detection of cancer. The company's product include Signal-C, a blood-based colorectal cancer screening test designed to detect colorectal cancer and pre-cancerous lesions. It offers clinical trials. UDX's products are used in the healthcare industry in cancer detection and prevention. The company collaborates with technological and medical institutions. It partners with several biobanks and hospitals. Universal DX is headquartered in Sevilla, Spain.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Universal Diagnostics SL
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company


Universal Diagnostics SL Company Overview
Universal Diagnostics SL Company Snapshot
Universal Diagnostics SL Pipeline Products and Ongoing Clinical Trials Overview
Universal Diagnostics SL – Pipeline Analysis Overview
Universal Diagnostics SL - Key Facts
Universal Diagnostics SL - Major Products and Services
Universal Diagnostics SL Pipeline Products by Development Stage
Universal Diagnostics SL Ongoing Clinical Trials by Trial Status
Universal Diagnostics SL Pipeline Products Overview
Blood-Based Diagnostic Test - Breast Cancer
Blood-Based Diagnostic Test - Breast Cancer Product Overview
Blood-Based Diagnostic Test - Colorectal Cancer
Blood-Based Diagnostic Test - Colorectal Cancer Product Overview
Multi-Cancer Detection Test
Multi-Cancer Detection Test Product Overview
Signal LU
Signal LU Product Overview
Signal-C
Signal-C Product Overview
Signal-C Clinical Trial
Signal-G
Signal-G Product Overview
Signal-L
Signal-L Product Overview
Signal-P
Signal-P Product Overview
Signal-X
Signal-X Product Overview
Universal Diagnostics SL - Key Competitors
Universal Diagnostics SL - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Universal Diagnostics SL, Recent Developments
Aug 15, 2024: Universal DX Initiates Clinical Trial for FDA Approval of Signal-C Colorectal Cancer Screening Blood Test
Nov 20, 2023: Universal Dx Announces Strategic Collaboration With Quest Diagnostics To Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
Nov 17, 2022: Universal DX presents methylation biomarker data at AACR special conference: precision prevention, early detection, and interception of cancer
Sep 12, 2022: New findings from Universal DX: Through a simple blood test, our body’s gut bacteria can help detect early-stage colorectal cancer
Jun 10, 2021: Universal DX presents data at EACR Virtual Congress; Top-Scoring poster shows accurate detection of colorectal advanced adenomas
Jun 03, 2021: Cancer prevention and early detection are one step closer as Universal DX announces breakthrough study results from its Multi-Omics + Computational Biology + ML Blood test
Mar 23, 2021: Universal Diagnostics initiates observational study in the US to evaluate cell free DNA blood test for adenomas and colorectal cancer
Jan 28, 2021: Universal Diagnostics presents promising data on lung cancer detection using blood-based methylation test at the IASLC 2020 World Conference on Lung Cancer
Sep 21, 2020: Universal Diagnostics presents new promising data on early (Pre) cancer detection from cell free DNA at European Society for Medical Oncology (ESMO)
Nov 20, 2017: Universal Diagnostics Starts Clinical Study of Novel Blood Screening Test for Early Detection of Colon Cancer with Imperial College Healthcare NHS Trust
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Universal Diagnostics SL Pipeline Products and Ongoing Clinical Trials Overview
Universal Diagnostics SL Pipeline Products by Equipment Type
Universal Diagnostics SL Pipeline Products by Indication
Universal Diagnostics SL Ongoing Clinical Trials by Trial Status
Universal Diagnostics SL, Key Facts
Universal Diagnostics SL, Major Products and Services
Universal Diagnostics SL Number of Pipeline Products by Development Stage
Universal Diagnostics SL Pipeline Products Summary by Development Stage
Universal Diagnostics SL Ongoing Clinical Trials by Trial Status
Universal Diagnostics SL Ongoing Clinical Trials Summary
Blood-Based Diagnostic Test - Breast Cancer - Product Status
Blood-Based Diagnostic Test - Breast Cancer - Product Description
Blood-Based Diagnostic Test - Colorectal Cancer - Product Status
Blood-Based Diagnostic Test - Colorectal Cancer - Product Description
Multi-Cancer Detection Test - Product Status
Multi-Cancer Detection Test - Product Description
Signal LU - Product Status
Signal LU - Product Description
Signal-C - Product Status
Signal-C - Product Description
Signal-C - A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
Signal-C - Collection of Samples from the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance (USOPTIVAL)
Signal-G - Product Status
Signal-G - Product Description
Signal-L - Product Status
Signal-L - Product Description
Signal-P - Product Status
Signal-P - Product Description
Signal-X - Product Status
Signal-X - Product Description
Universal Diagnostics SL, Other Locations
Glossary
List of Figures
Universal Diagnostics SL Pipeline Products by Equipment Type
Universal Diagnostics SL Pipeline Products by Development Stage
Universal Diagnostics SL Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings